Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®

Development of bio-therapeutics has exhibited exponential growth in China over the past decade. However, no biosimilar drug has been approved in China (CN) due to the lack of a national biosimilar regulatory guidance. HLX01, a rituximab biosimilar developed in China under European Medicines Agency b...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yanpeng, Xie, Liqi, Zhang, Erhui, Gao, Wenyuan, Wang, Linlin, Cao, Yang, Xie, Michael Hongwei, Jiang, Weidong, Liu, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512903/
https://www.ncbi.nlm.nih.gov/pubmed/30794092
http://dx.doi.org/10.1080/19420862.2019.1578147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512903/
https://www.ncbi.nlm.nih.gov/pubmed/30794092
http://dx.doi.org/10.1080/19420862.2019.1578147

Ejemplares similares